APO RESEARCH · REPORT
Aminoglycosides Antibiotics
Aminoglycosides are a class of antibiotics used mainly in the treatment of aerobic gram-negative bacilli infections, although they are also effective against other bacteria including Staphylococci and Mycobacterium tuberculosis. They are often used in combination with other antibiotics.
Product & engineering
Understand the product.
Aminoglycosides are a class of antibiotics used mainly in the treatment of aerobic gram-negative bacilli infections, although they are also effective against other bacteria including Staphylococci and Mycobacterium tuberculosis. They are often used in combination with other antibiotics.
Selected research
Industry Research
Aminoglycosides Antibiotics Industry Research Report 2026
Market perspective
Aminoglycosides are a class of antibiotics used mainly in the treatment of aerobic gram-negative bacilli infections, although they are also effective against other bacteria including Staphylococci and Mycobacterium tuberculosis. They are often used in combination with other antibiotics.
The classification of Aminoglycosides Antibiotics includes Neomycin, Tobramycin, Gentamicin, Amikacin, Etimicin and Others. In addition, the proportion of Neomycin in 2019 is about 26%, and Etimicin mainly sales in China.
Aminoglycosides Antibiotics is widely used for Hospital, Clinic, Post Care Facility, Government & Military and Others. The most proportion of Aminoglycosides Antibiotics is for clinic, and the proportion in 2019 is about 35%.
Read the full market overview
Europe is the largest consumption place, with a consumption market share nearly 26% in 2019. Following Europe, China is the second largest consumption place with the consumption market share of about 16%.
Jemicare, Teva, Novartis Pharmaceuticals, Fangyuan-pharma, Aike Pharmaceutical, Cipla, etc. are the leaders of the industry.
Report Scope
This report quantifies the global Aminoglycosides Antibiotics market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Aminoglycosides Antibiotics Market by Company
Jemicare
Teva
Novartis
Fangyuan-pharma
Aike Pharmaceutical
Cipla
Pfizer
Fresenius Kabi
Sun Pharma
Hikma
Lannett Company
Aminoglycosides Antibiotics Segment by Type
Neomycin
Tobramycin
Gentamicin
Amikacin
Etimicin
Others
Aminoglycosides Antibiotics Segment by Application
Hospital
Clinic
Post Care Facility
Government & Military
Others
Aminoglycosides Antibiotics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aminoglycosides Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Aminoglycosides Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aminoglycosides Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Aminoglycosides Antibiotics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Aminoglycosides Antibiotics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Aminoglycosides Antibiotics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Neomycin
- Tobramycin
- Gentamicin
- Amikacin
- Etimicin
- Others
Applications
- Hospital
- Clinic
- Post Care Facility
- Government & Military
- Others
Companies covered
- Jemicare
- Teva
- Novartis
- Fangyuan-pharma
- Aike Pharmaceutical
- Cipla
- Pfizer
- Fresenius Kabi
- Sun Pharma
- Hikma
- Lannett Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Aminoglycosides Antibiotics Market Size (2021-2032)
- 2.2.2 Global Aminoglycosides Antibiotics Sales (2021-2032)
- 2.2.3 Global Aminoglycosides Antibiotics Market Average Price (2021-2032)
- 2.3 Aminoglycosides Antibiotics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Neomycin
- 2.3.3 Tobramycin
- 2.3.4 Gentamicin
- 2.3.5 Amikacin
- 2.3.6 Etimicin
- 2.3.7 Others
- 2.4 Aminoglycosides Antibiotics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Post Care Facility
- 2.4.5 Government & Military
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Aminoglycosides Antibiotics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Aminoglycosides Antibiotics Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global Aminoglycosides Antibiotics Revenue of Manufacturers (2021-2026)
- 3.4 Global Aminoglycosides Antibiotics Average Price by Manufacturers (2021-2026)
- 3.5 Global Aminoglycosides Antibiotics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Aminoglycosides Antibiotics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Aminoglycosides Antibiotics, Product Type & Application
- 3.8 Global Manufacturers of Aminoglycosides Antibiotics, Established Date
- 3.9 Global Aminoglycosides Antibiotics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Jemicare
- 4.1.1 Jemicare Company Information
- 4.1.2 Jemicare Business Overview
- 4.1.3 Jemicare Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Jemicare Aminoglycosides Antibiotics Product Portfolio
- 4.1.5 Jemicare Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Aminoglycosides Antibiotics Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Aminoglycosides Antibiotics Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Fangyuan-pharma
- 4.4.1 Fangyuan-pharma Company Information
- 4.4.2 Fangyuan-pharma Business Overview
- 4.4.3 Fangyuan-pharma Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fangyuan-pharma Aminoglycosides Antibiotics Product Portfolio
- 4.4.5 Fangyuan-pharma Recent Developments
- 4.5 Aike Pharmaceutical
- 4.5.1 Aike Pharmaceutical Company Information
- 4.5.2 Aike Pharmaceutical Business Overview
- 4.5.3 Aike Pharmaceutical Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Aike Pharmaceutical Aminoglycosides Antibiotics Product Portfolio
- 4.5.5 Aike Pharmaceutical Recent Developments
- 4.6 Cipla
- 4.6.1 Cipla Company Information
- 4.6.2 Cipla Business Overview
- 4.6.3 Cipla Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cipla Aminoglycosides Antibiotics Product Portfolio
- 4.6.5 Cipla Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Aminoglycosides Antibiotics Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Fresenius Kabi
- 4.8.1 Fresenius Kabi Company Information
- 4.8.2 Fresenius Kabi Business Overview
- 4.8.3 Fresenius Kabi Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Fresenius Kabi Aminoglycosides Antibiotics Product Portfolio
- 4.8.5 Fresenius Kabi Recent Developments
- 4.9 Sun Pharma
- 4.9.1 Sun Pharma Company Information
- 4.9.2 Sun Pharma Business Overview
- 4.9.3 Sun Pharma Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sun Pharma Aminoglycosides Antibiotics Product Portfolio
- 4.9.5 Sun Pharma Recent Developments
- 4.10 Hikma
- 4.10.1 Hikma Company Information
- 4.10.2 Hikma Business Overview
- 4.10.3 Hikma Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hikma Aminoglycosides Antibiotics Product Portfolio
- 4.10.5 Hikma Recent Developments
- 4.11 Lannett Company
- 4.11.1 Lannett Company Company Information
- 4.11.2 Lannett Company Business Overview
- 4.11.3 Lannett Company Aminoglycosides Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Lannett Company Aminoglycosides Antibiotics Product Portfolio
- 4.11.5 Lannett Company Recent Developments
5 Global Aminoglycosides Antibiotics Market Scenario by Region
- 5.1 Global Aminoglycosides Antibiotics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Aminoglycosides Antibiotics Sales by Region: 2021-2032
- 5.2.1 Global Aminoglycosides Antibiotics Sales by Region: 2021-2026
- 5.2.2 Global Aminoglycosides Antibiotics Sales by Region: 2027-2032
- 5.3 Global Aminoglycosides Antibiotics Revenue by Region: 2021-2032
- 5.3.1 Global Aminoglycosides Antibiotics Revenue by Region: 2021-2026
- 5.3.2 Global Aminoglycosides Antibiotics Revenue by Region: 2027-2032
- 5.4 North America Aminoglycosides Antibiotics Market Facts & Figures by Country
- 5.4.1 North America Aminoglycosides Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Aminoglycosides Antibiotics Sales by Country (2021-2032)
- 5.4.3 North America Aminoglycosides Antibiotics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Aminoglycosides Antibiotics Market Facts & Figures by Country
- 5.5.1 Europe Aminoglycosides Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Aminoglycosides Antibiotics Sales by Country (2021-2032)
- 5.5.3 Europe Aminoglycosides Antibiotics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Aminoglycosides Antibiotics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Aminoglycosides Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Aminoglycosides Antibiotics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Aminoglycosides Antibiotics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Aminoglycosides Antibiotics Market Facts & Figures by Country
- 5.7.1 South America Aminoglycosides Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Aminoglycosides Antibiotics Sales by Country (2021-2032)
- 5.7.3 South America Aminoglycosides Antibiotics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Aminoglycosides Antibiotics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Aminoglycosides Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Aminoglycosides Antibiotics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Aminoglycosides Antibiotics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Aminoglycosides Antibiotics Sales by Type (2021-2032)
- 6.1.1 Global Aminoglycosides Antibiotics Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global Aminoglycosides Antibiotics Sales Market Share by Type (2021-2032)
- 6.2 Global Aminoglycosides Antibiotics Revenue by Type (2021-2032)
- 6.2.1 Global Aminoglycosides Antibiotics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Aminoglycosides Antibiotics Revenue Market Share by Type (2021-2032)
- 6.3 Global Aminoglycosides Antibiotics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Aminoglycosides Antibiotics Sales by Application (2021-2032)
- 7.1.1 Global Aminoglycosides Antibiotics Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global Aminoglycosides Antibiotics Sales Market Share by Application (2021-2032)
- 7.2 Global Aminoglycosides Antibiotics Revenue by Application (2021-2032)
- 7.2.1 Global Aminoglycosides Antibiotics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Aminoglycosides Antibiotics Revenue Market Share by Application (2021-2032)
- 7.3 Global Aminoglycosides Antibiotics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Aminoglycosides Antibiotics Value Chain Analysis
- 8.1.1 Aminoglycosides Antibiotics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Aminoglycosides Antibiotics Production Mode & Process
- 8.2 Aminoglycosides Antibiotics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Aminoglycosides Antibiotics Distributors
- 8.2.3 Aminoglycosides Antibiotics Customers
9 Global Aminoglycosides Antibiotics Analyzing Market Dynamics
- 9.1 Aminoglycosides Antibiotics Industry Trends
- 9.2 Aminoglycosides Antibiotics Industry Drivers
- 9.3 Aminoglycosides Antibiotics Industry Opportunities and Challenges
- 9.4 Aminoglycosides Antibiotics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst